2. Search Result
Search Result
Results for "

helicase activity

" in MedChemExpress (MCE) Product Catalog:

52

Inhibitors & Agonists

2

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-158116
    VVD-214

    RO7589831; VVD-133214

    		 DNA/RNA Synthesis Cancer
    VVD-214 is a synthetic lethal allosteric inhibitor of WRN helicase with an IC50 of 0.1316 µM. VVD-214 covalently binds to cysteine 727 of WRN and inhibits ATP hydrolysis and helicase activity. VVD-214 is potent in causing double-stranded DNA breaks, nuclear swelling, and cell death in high microsatellite instability (MSI) cancers .
    VVD-214
  • HY-14809
    Amenamevir
    5+ Cited Publications

    ASP2151

    		 HSV Infection
    Amenamevir is a helicase-primase inhibitor which has potent antiviral activity against HSVs with an EC50 of 14 ng/mL.
    Amenamevir
  • HY-100455
    RK-33
    5 Publications Verification

    		 DNA/RNA Synthesis SARS-CoV Cancer
    RK-33 is an RNA helicase inhibitor against DDX3, and inhibits its helicase activity.
    RK-33
  • HY-12342
    ML216
    5+ Cited Publications

    CID-49852229

    		 DNA/RNA Synthesis Cancer
    ML216 (CID-49852229) is a potent, selective and cell permeable inhibitor of the DNA unwinding activity of BLM helicase with IC50s of 2.98 μM and 0.97 μM for BLM full-length and BLM 636-1298, respectively. ML216 inhibits ssDNA-dependent ATPase activity of BLM with a Ki of 1.76 μM. Antitumor avtivity .
    ML216
  • HY-128729
    DNA2 inhibitor C5
    Maximum Cited Publications
    10 Publications Verification

    		 DNA/RNA Synthesis Cancer
    DNA2 inhibitor C5 is a potent, competitive, and specific DNA2 nuclease inhibitor with an IC50 of 20 μM. DNA2 inhibitor C5 inhibits the nuclease, DNA-dependent ATPase, helicase, and DNA-binding activities of DNA2. DNA2 inhibitor C5 can be used in breast cancer and colorectal cancer research .
    DNA2 inhibitor C5
  • HY-15303
    Pritelivir
    5+ Cited Publications

    AIC316; BAY 57-1293

    		 DNA/RNA Synthesis HSV Infection
    Pritelivir (AIC316), an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. Pritelivir is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC50 of 0.02 μM against HSV1-2 .
    Pritelivir
  • HY-164421
    PhpC

    		G-quadruplex DNA/RNA Synthesis Cancer
    PhpC is a G-quadruplex (G4)-DNA/RNA disruptor. PhpC disrupts DNA and RNA G4 structures and promotes G4 helicase activity. PhpC effectively enhancing the activity of Taq polymerase. PhpC modulates G-quadruplexs (G4s) both in vitro and in cells .
    PhpC
  • HY-122903
    TK216
    5+ Cited Publications

    		 DNA/RNA Synthesis Cancer
    TK216 is an orally active and potent E26 transformation specific (ETS) inhibitor . TK216 directly binds EWS-FLI1 and inhibits EWS-FLI1 protein interactions. TK216 blocks the binding between EWS-FLI1 and RNA helicase A. TK216 has anticancer activity .
    TK216
  • HY-148740
    Werner syndrome RecQ helicase-IN-3

    		DNA/RNA Synthesis Cancer
    Werner syndrome RecQ helicase-IN-3 is a potent and orally active werner syndrome recQ helicase (WRN) inhibitor with an IC50 value of 0.06 µM. Werner syndrome RecQ helicase-IN-3 shows antiproliferative activity. Werner syndrome RecQ helicase-IN-3 shows anticancer activity .
    Werner syndrome RecQ helicase-IN-3
  • HY-175750
    MOMA-341

    		DNA/RNA Synthesis Cancer
    MOMA-341 is a selective Werner RecQ like helicase (WRN) inhibitor. MOMA-341 binds to WRN at cysteine 727 through an allosteric and ATP-competitive binding mechanism. MOMA-341 has antitumor activity and can be used for advanced and metastatic solid tumors research .
    MOMA-341
  • HY-14507
    YK-4-279
    5+ Cited Publications

    		 DNA/RNA Synthesis Apoptosis Cancer
    YK-4-279 blocks RNA Helicase A (RHA) binding with EWS-FLI1 (oncogenic protein). YK-4-279 induces apoptosis and shows anti-proliferation activities towards various cancer cells. YK-4-279 has a chiral center and it can be separated into two enantiomers. YK-4-279 can be used for the research of cancer .
    YK-4-279
  • HY-156782
    DHX9-IN-1
    1 Publications Verification

    		 DNA/RNA Synthesis Cancer
    DHX9-IN-1 is an inhibitor of ATP-dependent RNA helicase A (DHX9). Its EC50 value is 1.41 μM. DHX9-IN-1 has anti-tumor activity and can be used in colorectal cancer research .
    DHX9-IN-1
  • HY-33838
    eIF4A3-IN-8

    		Eukaryotic Initiation Factor (eIF) Others
    eIF4A3-IN-8 serves as a negative control targeting eukaryotic initiation factor 4A3 (eIF4A3), with an IC50 > 100 μM; it exhibits no significant activity .
    eIF4A3-IN-8
  • HY-145685
    RECQL5-IN-1

    		DNA/RNA Synthesis Cancer
    RECQL5-IN-1 (Compound 4a) acts as an orally effective RECQL5 inhibitor (targeting both enzymatic and nonenzymatic domain). RECQL5-IN-1 is a potent inhibitor of RECQL5 helicase activity (IC50=46.3 nM), stabilizes the interaction between RECQL5-RAD51 proteins, causes RAD51 aggregation and homologous recombination repair (HRR) inhibition, thereby exhibiting selective cytotoxicity in RECQL5-expressing cancer cells .
    RECQL5-IN-1
  • HY-N6935
    Sennidin B

    		DNA/RNA Synthesis HCV Akt GLUT Infection Metabolic Disease
    Sennidin B, a stereoisomer isolated from the leaves of Cassia angustifolia, has lower activity than Sennidin A. Sennidin A inhibits HCV NS3 helicase, with an IC50 of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Sennidin A stimulates the glucose incorporation .
    Sennidin B
  • HY-162471
    GSK_WRN3

    		DNA/RNA Synthesis ATM/ATR Cancer
    GSK_WRN3 is selective WRN helicase inhibitor (pIC50 = 8.6). SK_WRN3 can selectively inhibit the growth of microsatellite unstable (MSI) cancer cells, induce DNA damage, and cause cell cycle arrest. GSK_WRN3 has anti-tumor activity .
    GSK_WRN3
  • HY-137820
    Brr2-IN-3

    		DNA/RNA Synthesis Others
    Brr2-IN-3 is a potent and selective Brr2 helicase allosteric Inhibitor. Brr2-IN-3 inhibits helicase activity in dose-dependent manner with an IC50 value of 1.3 μM .
    Brr2-IN-3
  • HY-15303A
    Pritelivir mesylate
    5+ Cited Publications

    AIC316 mesylate; BAY 57-1293 mesylate

    		 DNA/RNA Synthesis HSV Infection
    Pritelivir mesylate (BAY 57-1293 mesylate), an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. Pritelivir mesylate is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC50 of 0.02 μM against HSV1-2 .
    Pritelivir mesylate
  • HY-148741
    Werner syndrome RecQ helicase-IN-4

    		DNA/RNA Synthesis Cancer
    Werner syndrome RecQ helicase-IN-4 is a potent and orally active werner syndrome recQ helicase (WRN) inhibitor with an IC50 value of 0.06 µM. Werner syndrome RecQ helicase-IN-4 shows antiproliferative activity. Werner syndrome RecQ helicase-IN-4 shows anticancer activity .
    Werner syndrome RecQ helicase-IN-4
  • HY-176268
    SGC-NSP2hel-1

    RA-0188293; RA-NSP2-1

    		 DNA/RNA Synthesis Virus Protease Flavivirus Infection
    SGC-NSP2hel-1 (RA-0188293), a chemical probe, is a potent, specific and orally active nsP2 inhibitor. SGC-NSP2hel-1 has broad spectrum activity against multiple alphaviruses of the nsP2 helicase with a CC50 > 250 μM. SGC-NSP2hel-1 (RA-0188293) shows selectivity index > 4000 against human RNA helicases. SGC-NSP2hel-1 reduces virus replication and limited virus-induced pathology by forming a stable complex with nsP2 and ATP in a preclinical small animal model of CHIKV disease.
    SGC-NSP2hel-1
  • HY-122903S
    TK216-d4

    		Isotope-Labeled Compounds DNA/RNA Synthesis Cancer
    TK216-d4 is the deuterium labeled TK216 (HY-122903). TK216 is an orally active and potent E26 transformation specific (ETS) inhibitor . TK216 directly binds EWS-FLI1 and inhibits EWS-FLI1 protein interactions. TK216 blocks the binding between EWS-FLI1 and RNA helicase A. TK216 has anticancer activity .
    TK216-d4
  • HY-161916
    Polθ-IN-4

    		DNA/RNA Synthesis Cancer
    Polθ-IN-4 is an orally active prodrug of a DNA polymerase θ (Polθ) inhibitor with Kms of 3.7, 3.7 and 5.2 μM in human, mouse and rat recombinant alkaline phosphatases. Polθ-IN-4 that inhibits Polθ activity by targeting its ATP-dependent helicase domain. Polθ-IN-4 demonstrates significant anti-tumor activity in multiple animal experiments. Polθ-IN-4 can be used for the studies of breast cancer and ovarian cancer .
    Polθ-IN-4
  • HY-153692
    WRN inhibitor 1

    		DNA/RNA Synthesis Cancer
    WRN inhibitor 1 is a Wemer Syndrome ATP dependent helicase enzyme (WRN) inhibitor that inhibits WRN helicase domain activity. WRN inhibitor 1 can be used in the study of cancer .
    WRN inhibitor 1
  • HY-15303B
    Pritelivir mesylate hydrate
    5+ Cited Publications

    AIC316 mesylate hydrate; BAY 57-1293 mesylate hydrate

    		 DNA/RNA Synthesis HSV Infection
    Pritelivir mesylate hydrate (BAY 57-1293 mesylate hydrate), an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. Pritelivir mesylate hydrate is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC50 of 0.02 μM against HSV1-2 .
    Pritelivir mesylate hydrate
  • HY-169423
    WRN inhibitor 17

    		DNA/RNA Synthesis Cancer
    WRN inhibitor 17 (Compound 250) is an orally active Werner Syndrome ATP dependent helicase enzyme (WRN) inhibitor, in particular inhibit WRN helicase domain activity. WRN inhibitor 17 is promising for research of cancers .
    WRN inhibitor 17
  • HY-14809R
    Amenamevir (Standard)

    ASP2151 (Standard)

    		 Reference Standards HSV Infection
    Amenamevir (Standard) is the analytical standard of Amenamevir. This product is intended for research and analytical applications. Amenamevir is a helicase-primase inhibitor which has potent antiviral activity against HSVs with an EC50 of 14 ng/mL.
    Amenamevir (Standard)
  • HY-161386
    WRN inhibitor 7

    		DNA/RNA Synthesis Cancer
    WRN inhibitor 7 (Compound h6) is a WRN inhibitor. WRN inhibitor 7 effectively inhibits WRN's helicase and ATPase activity (IC50: 9.8 μM and 15.8 μM respectively). WRN inhibitor 7 can be used for research of microsatellite instable (MSI) cancers .
    WRN inhibitor 7
  • HY-129767
    CMLD012612

    		Eukaryotic Initiation Factor (eIF) Cancer
    CMLD012612 is an amidino-rocaglate containing a hydroxamate group and is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. CMLD012612 inhibits cell translation and is cytotoxic to NIH/3T3 cells with an IC50 value of 2 nM. CMLD012612 inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase (eIF4A) and possesses potent anti-neoplastic activity .
    CMLD012612
  • HY-15303AR
    Pritelivir mesylate (Standard)

    AIC316 mesylate (Standard); BAY 57-1293 mesylate (Standard)

    		 HSV Reference Standards Infection
    Pritelivir (mesylate) (Standard) is the analytical standard of Pritelivir (mesylate). This product is intended for research and analytical applications. Pritelivir mesylate (BAY 57-1293 mesylate), an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. Pritelivir mesylate is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC50 of 0.02 μM against HSV1-2 .
    Pritelivir mesylate (Standard)
  • HY-15303R
    Pritelivir (Standard)

    AIC316 (Standard); BAY 57-1293 (Standard)

    		 HSV Reference Standards Infection
    Pritelivir (Standard) is the analytical standard of Pritelivir. This product is intended for research and analytical applications. Pritelivir (AIC316), an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. Pritelivir is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC50 of 0.02 μM against HSV1-2 .
    Pritelivir (Standard)
  • HY-146379
    SARS-CoV-2-IN-19

    		DNA/RNA Synthesis SARS-CoV Infection
    SARS-CoV-2-IN-19 (Compound 6g) is a potent inhibitor of SARS-CoV-2 with an EC50 of 8.8 μM. SARS-CoV-2-IN-19 shows potent activity against SARS-CoV-2 helicase (nsp13), a highly conserved enzyme, highlighting a potentiality against emerging HCoVs outbreaks. SARS-CoV-2-IN-19 has the potential for the research of infection diseases .
    SARS-CoV-2-IN-19
  • HY-128729R
    DNA2 inhibitor C5 (Standard)

    		Reference Standards DNA/RNA Synthesis Cancer
    DNA2 inhibitor C5 (Standard) is the analytical standard of DNA2 inhibitor C5 (HY-128729). This product is intended for research and analytical applications. DNA2 inhibitor C5 is a potent, competitive, and specific DNA2 nuclease inhibitor with an IC50 of 20 μM. DNA2 inhibitor C5 inhibits the nuclease, DNA-dependent ATPase, helicase, and DNA-binding activities of DNA2. DNA2 inhibitor C5 can be used in breast cancer and colorectal cancer research.
    DNA2 inhibitor C5 (Standard)
  • HY-145115
    Adeninobananin

    		DNA/RNA Synthesis Infection
    Adeninobananin, a negative control tool, does not show any inhibitory activity of the SARS Coronavirus helicase.
    Adeninobananin
  • HY-176727
    WRN inhibitor 19

    		DNA/RNA Synthesis Cancer
    WRN inhibitor 19 (Compound 40) is a WRN helicase inhibitor (IC50: 3.7 nM). WRN inhibitor 19 exhibits selective antiproliferative activity in WRN-dependent cancer cells. WRN inhibitor 19 inhibits WRN helicase function by competitively binding to the ATP site and induces DNA damage and cell cycle arrest. WRN inhibitor 19 can be used in the study of WRN-dependent cancers .
    WRN inhibitor 19
  • HY-158025
    Anticancer agent 198

    		DNA/RNA Synthesis Cancer
    Anticancer agent 198 (compound 18b) is a potent anticancer agent and potential WRN protein inhibitor. Anticancer agent 198 was significantly toxic to K562 cells and WRN-overexpressing PC3 cells .
    Anticancer agent 198
  • HY-152259
    TMV-IN-4

    		DNA/RNA Synthesis TMV Infection
    TMV-IN-4 (compound 3) is a tobacco mosaic virus (TMV) inhibitor that effectively induces resistance and enhances plant tolerance to TMV infection by interacting with TMV helicase. TMV-IN-4 enhances peroxidase and superoxide dismutase activity, thereby increasing resistance to TMV in tobacco .
    TMV-IN-4
  • HY-163325A
    Fli-1-IN-1

    		DNA/RNA Synthesis Cancer
    Fli-1-IN-1 (compound 21) is a FLI1 targeting agent that directly binds to and inhibits the EWS-FLI1 protein interaction. EWS-FLI1 can bind to RNA helicase A, and Fli-1-IN-1 inhibits EWS-FLI1 and has potential anticancer activity .
    Fli-1-IN-1
  • HY-163325
    Fli-1-IN-1 fumarate

    		DNA/RNA Synthesis Cancer
    Fli-1-IN-1 (compound 21) fumarate is a FLI1 targeting agent that directly binds to and inhibits the EWS-FLI1 protein interaction. EWS-FLI1 can bind to RNA helicase A, and Fli-1-IN-1 fumarate inhibits EWS-FLI1 and has potential anticancer activity .
    Fli-1-IN-1 fumarate
  • HY-N6935R
    Sennidin B (Standard)

    		Reference Standards HCV Akt GLUT Infection Metabolic Disease
    Sennidin B (Standard) is the analytical standard of Sennidin B. This product is intended for research and analytical applications. Sennidin B, a stereoisomer isolated from the leaves of Cassia angustifolia, has lower activity than Sennidin A. Sennidin A inhibits HCV NS3 helicase, with an IC50 of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Sennidin A stimulates the glucose incorporation .
    Sennidin B (Standard)
  • HY-150625
    SARS-CoV-2 nsp13-IN-4

    		DNA/RNA Synthesis SARS-CoV Infection
    SARS-CoV-2 nsp13-IN-4 (C4 (d)) is a potent and selective nsp13 helicase small-molecule inhibitor and inhibit the ssDNA+ ATPase activity of nsp13 with an IC50 value of 57 μM. SARS-CoV-2 nsp13-IN-4 is agentlike molecule with molecular weight of less than 450Da and can provide a broad-spectrum antiviral effect .
    SARS-CoV-2 nsp13-IN-4
  • HY-15303S
    Pritelivir-d4-1

    AIC316-d4-1; BAY 57-1293-d4-1

    		 Isotope-Labeled Compounds HSV DNA/RNA Synthesis Infection
    Pritelivir-d4-1 (AIC316-d4-1) is deuterium labeled Pritelivir. Pritelivir (AIC316), an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. Pritelivir is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC50 of 0.02 μM against HSV1-2 .
    Pritelivir-d4-1
  • HY-175234
    CHIKV nsP2 protease-IN-2

    		DNA/RNA Synthesis Virus Protease Infection
    CHIKV nsP2 protease-IN-2 (Compound 2o) is a allosteric nonstructural protein 2 helicase (nsP2hel) inhibitor with IC50s of 0.5  μM and 0.9  μM for nsP2 ATPase and RNA unwindase, respectively. CHIKV nsP2 protease-IN-2 has broad-spectrum antialphaviral activity against chikungunya virus (CHIKV), Mayaro virus (MAYV), and Venezuelan equine encephalitis virus (VEEV) (EC50 of 120 nM for CHIKV-nLuc). CHIKV nsP2 protease-IN-2 can be used for alphaviruses infections research .
    CHIKV nsP2 protease-IN-2
  • HY-181557
    SY-589

    		DNA Alkylator/Crosslinker DNA/RNA Synthesis Apoptosis Cancer
    SY-589 is an orally active DNA polymerase Polθ helicase domain inhibitor (IC50=2.29 nM) and DNA damage inducer. SY-589 inhibits the ATPase activity of the Polθ helicase domain and blocks the Polθ-mediated microhomology-mediated end joining (MMEJ) DNA repair pathway (IC50=0.85 nM). SY-589 also induces the accumulation of DNA double-strand breaks by increasing γ-H2AX levels. SY-589 exerts antiproliferative effects on BRCA2-deficient cells and is used in the research of HR-deficient tumors .
    SY-589
  • HY-117802
    CID-50930756

    		DNA/RNA Synthesis HCV HCV Protease Infection
    CID-50930756 is an HCV NS3 helicase inhibitor with an IC50 of 22 μM.CID-50930756 inhibits HCV NS3 helicase-catalyzed nucleic acid unwinding.CID-50930756 inhibits HCV replication in hepatoma cells harboring a stably transfected subgenomic HCV replicon.CID-50930756 does not exhibit toxicity to hepatoma cells at 10 μM.CID-50930756 shows weak DNA-binding activity, displacing less than 20% of SYBR Green I from DNA at 100 μM.CID-50930756 can be used for the research of hepatitis c .
    CID-50930756
  • HY-182634
    NCGC00063279

    		DNA/RNA Synthesis Phosphatase Cancer
    NCGC00063279 is a reversible Werner Syndrome Helicase-Nuclease (WRN) helicase inhibitor with modest selectivity over BLM and FANCJ helicases, and does not inhibit WRN exonuclease activity at active concentrations. NCGC00063279 inhibits Hematopoietic Protein Tyrosine Phosphatase (HePTP) and reduces proliferation of cancer cells. NCGC00063279 can be used for the research of osteosarcoma .
    NCGC00063279
  • HY-100455R
    RK-33 (Standard)

    		DNA/RNA Synthesis Reference Standards SARS-CoV Cancer
    RK-33 (Standard) is the analytical standard of RK-33 (HY-100455). This product is intended for research and analytical applications. RK-33 is an RNA helicase inhibitor against DDX3, and inhibits its helicase activity.
    RK-33 (Standard)
  • HY-179326
    WRN-IN-23

    		DNA/RNA Synthesis Cancer
    WRN-IN-23 is a Werner Syndrome helicase enzyme (WRN) inhibitor. WRN-IN-23 inhibits the ATP-dependent helicase domain activity of WRN. WRN-IN-23 can be used for the research of cancers characterized by microsatellite instability (MSI) and/or defective DNA mismatch repair system (dMMR) .
    WRN-IN-23
  • HY-150306B
    (R)-Adibelivir

    (R)-IM-250

    		 HSV DNA/RNA Synthesis Infection
    (R)-Adibelivir ((R)-IM-250) is a blood-brain barrier-permeable HSV helicase-primase inhibitor. (R)-Adibelivir specifically inhibits the activity of the HSV UL5-UL52-UL8 helicase-primase complex. (R)-Adibelivir affects viral reactivation and significantly reduces the reactivation capacity of latent neuronal HSV reservoirs. (R)-Adibelivir can be used in studies related to herpes simplex virus infection, herpes encephalitis, neonatal herpes, and other related conditions .
    (R)-Adibelivir
  • HY-W752451
    Amenamevir-d6

    ASP2151-d6

    		 Isotope-Labeled Compounds HSV Infection
    Amenamevir-d6 (ASP2151-d6) is the deuterium labeled Amenamevir (HY-14809). Amenamevir is a helicase-primase inhibitor which has potent antiviral activity against HSVs with an EC50 of 14 ng/mL.
    Amenamevir-d6
  • HY-181562
    WRN-IN-24

    		DNA/RNA Synthesis Cancer
    WRN-IN-24 is an orally active allosteric covalent Werner syndrome helicase (WRN) inhibitor with an IC50 of 201 nM. WRN-IN-24 binds to a novel allosteric cavity, forms an additional hydrogen bond with K894, and functionally inhibits WRN activity. WRN-IN-24 inhibits colorectal cancer cells proliferation and exerts dose-dependent antitumor activity in xenograft mouse models. WRN-IN-24 can be used for the research of microsatellite instability-high cancers, including colorectal cancer .
    WRN-IN-24

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: